Malignant neoplasm of breast, HER-negative (controls excluding all cancers)

C3_BREAST_ERNEG_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector
diagram bullet

Apply sex-specific rule

Sex only females

diagram downward connector
diagram bullet

Check conditions

not RX_ERPLUS

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C50
Cause of death: ICD-9 174
Cause of death: ICD-8 174
Cancer registry: Topography ICD-O-3 C50
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes [23]

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

5965

diagram downward connector
C3_BREAST_ERNEG_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE
Control conditions not RX_ERPLUS

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF9

Summary Statistics

Key figures

All Female Male
Number of individuals 5965 5965 -
Unadjusted prevalence (%) 1.58 2.83 -
Mean age at first event (years) 57.56 57.56 -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.03 1.52 [1.10, 2.11] 1.1e-2 674
15 years 0.01 0.86 [0.66, 1.11] 2.5e-1 239
5 years 0.00 2.21 [1.77, 2.77] 4.2e-12 186
1 year 0.00 6.09 [4.68, 7.93] 3.3e-41 103

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: C3_BREAST_ERNEG_EXALLC – Malignant neoplasm of breast, HER-negative (controls excluding all cancers)
GWS hits: 13

Survival analyses between endpoints

Plot

before Malignant neoplasm of breast, HER-negative (controls excluding all cancers)
after Malignant neoplasm of breast, HER-negative (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Malignant neoplasm of breast, HER-negative (controls excluding all cancers)

Endpoint not on priority list, no data to show.